NAD Injection Side Effects: What Every Patient Should Know Before Treatment

NAD injections and intravenous (IV) NAD+ infusions are increasingly marketed in wellness settings for goals such as energy, cognition, recovery, and healthy aging. However, evidence for these clinical benefits remains limited, and injectable NAD+ products are not FDA-approved treatments for these purposes.

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme involved in cellular metabolism, redox reactions, and signaling. Injectable and IV NAD+ bypass the gastrointestinal tract, but human pharmacokinetic and clinical data on directly administered NAD+ remain limited. A 2019 pilot study of a six-hour IV NAD+ infusion documented changes in NAD+-related metabolites during and after infusion, but it did not establish broad clinical benefits or a complete safety profile.

Reported reactions to NAD injections and IV infusions range from mild, short-lived symptoms to more significant infusion-related events. Because controlled safety data are limited, the true frequency of specific NAD injection side effects is not well established. Product quality, formulation, route of administration, dose, infusion rate, and individual health factors may all affect risk.

This guide reviews what is currently known about reported NAD injection side effects, how IV and intramuscular administration differ, what FDA has reported about compounded injectable NAD+, and when symptoms warrant medical attention.

What Are NAD Injections and How Do They Work?

NAD injections generally refer to compounded products containing nicotinamide adenine dinucleotide that are administered intramuscularly. IV NAD+ is infused directly into a vein. There is no FDA-approved NAD+ injection with standardized labeling for wellness, energy, anti-aging, or cognitive indications, so formulation, concentration, administration protocols, and monitoring practices can vary between providers.

Understanding Nicotinamide Adenine Dinucleotide Side Effects

The reasons people experience symptoms during or after NAD administration are not fully established. Some reactions may relate to the route of administration, infusion rate, dose, formulation, excipients, contamination, or product quality rather than to a predictable cellular “adjustment” to NAD+ itself.

This distinction matters because symptoms such as chest pressure, vomiting, severe chills, or marked changes in heart rate should not automatically be interpreted as a normal sign that NAD+ is “working.” They should be assessed by the treating clinician.

NAD+ Injection vs NAD IV Treatment Differences

Intramuscular NAD shots and IV NAD+ differ in route, treatment time, volume, and monitoring. IV administration can produce symptoms during the infusion, while intramuscular injections may also cause local injection-site reactions.

There is not enough comparative clinical evidence to conclude that one route has a lower overall side-effect rate or greater clinical effectiveness. Route selection should be based on the specific formulation, treatment setting, clinician judgment, and patient-specific considerations rather than an assumption that one method is inherently safer or more effective.

Reported NAD Injection Side Effects

Short-Term Symptoms Reported With NAD Administration

Human data remain limited, but symptoms reported during or after NAD+ administration include:

• Nausea or gastrointestinal discomfort

• Fatigue

• Headache

• Flushing or warmth

• Increased heart rate

• Chest pressure or tightness

• Muscle cramping

• Dizziness or lightheadedness

A 2026 retrospective real-world tolerability study compared commercially administered IV NAD+ with IV nicotinamide riboside. Participants receiving NAD+ reported moderate to severe gastrointestinal symptoms, increased heart rate, and chest pressure during infusions; the reported symptoms resolved when the infusions ended. The study was small, observational, and followed participants for only 30 days, so it provides preliminary tolerability data rather than a definitive safety profile.

The available evidence does not establish how frequently these symptoms occur after intramuscular NAD injections specifically, how long they usually last, or which doses are more likely to produce them.

Injection-Site Reactions and Local Symptoms

Intramuscular injections can cause local soreness, redness, swelling, bruising, tenderness, or irritation at the injection site. These reactions can occur with many injected medications, but specific frequency and duration data for NAD injections are limited.

Persistent or worsening redness, warmth, drainage, severe pain, fever, or significant swelling should be assessed by a healthcare professional because these findings can also occur with infection or other injection-related complications.

NAD IV Treatment Side Effects vs Injection Side Effects

Can NAD Be Harmful When Delivered Intravenously?

The safety profile of IV NAD+ is not yet well characterized. Limited human research describes infusion-related symptoms, and FDA has also received adverse-event reports associated with compounded NAD+ injectable products.

FDA has reported severe chills, shaking, vomiting, and fatigue after use of certain compounded NAD+ injectables, with some cases requiring medical treatment. FDA noted that the reactions were consistent with excessive endotoxin exposure and warned compounders not to use ingredients intended for foods or dietary supplements in sterile injectable products without appropriate processing.

Chest pressure, increased heart rate, gastrointestinal symptoms, and cramping have also been reported during IV NAD+ administration. If significant symptoms occur during an infusion, the treating clinician should evaluate them rather than assuming a specific benign cause.

NAD IV Drips vs NAD Shots: What Can We Actually Compare?

Intramuscular injections may be associated with local injection-site reactions, while IV infusions allow symptoms to be observed during administration and the infusion to be adjusted or stopped. However, there is currently insufficient evidence to rank IV NAD+ and intramuscular NAD injections by overall safety or effectiveness.

There is also insufficient evidence to conclude that IV NAD+ provides greater clinical benefits than intramuscular NAD. Comparisons should therefore be made cautiously.

Serious NAD+ Side Effects and When to Seek Help

Serious complications appear to be uncommon in the limited published literature, but the absence of large controlled safety studies means the true risk is uncertain. Seek urgent medical attention for symptoms such as:

• Difficulty breathing, throat tightness, or facial swelling

• Widespread hives or a rapidly spreading rash

• Severe or persistent chest pain or chest pressure

• Fainting or severe lightheadedness

• Severe vomiting or inability to keep fluids down

• High fever, severe chills, or uncontrollable shaking

• Rapidly worsening pain, redness, swelling, warmth, or drainage at an injection site

Allergic Reactions

The frequency of allergic reactions to NAD injections is not well established. Reactions may involve NAD+, excipients, preservatives, contaminants, or other components of a compounded formulation. Because compounded preparations can differ, a reaction to one product does not necessarily identify the exact responsible ingredient.

Breathing difficulty, facial or throat swelling, or widespread hives can indicate a serious allergic reaction and warrant emergency care.

Metabolic and Longer-Term Concerns

Evidence is currently insufficient to define specific metabolic adverse effects of NAD injections or to establish a comprehensive long-term safety profile. People with diabetes, liver disease, kidney disease, cardiovascular disease, cancer, or other chronic conditions should discuss NAD injections with a qualified healthcare professional because clinical data in these populations are limited.

Long-term safety data for repeated injectable or IV NAD+ therapy are also insufficient. There is currently no evidence-based treatment-cycling schedule that can be recommended universally.

Side Effects of NAD Supplements vs Injectable Forms

Oral NAD-related supplements, NAD precursors, sublingual products, intramuscular NAD injections, and IV NAD+ are not interchangeable. They differ in formulation, absorption, metabolism, and the quality of available evidence.

There is not enough direct comparative evidence to rank these approaches reliably by safety, bioavailability, or clinical effectiveness. Evidence from oral NAD precursors should not automatically be applied to direct NAD+ injections or IV infusions.

Is NAD IV Therapy Safe? What FDA and Current Evidence Say

FDA Status and Regulatory Considerations

Injectable NAD+ is not an FDA-approved drug for treating fatigue, cognitive decline, aging, or other wellness indications. Compounded NAD+ products are also not FDA-approved and do not undergo FDA premarket review for safety, effectiveness, or quality.

FDA has specifically warned compounders about using ingredients unsuitable for sterile NAD+ products after receiving adverse-event reports associated with injectable NAD+.

A January 2026 FDA warning letter involving a compounded NAD+ product described patients who developed symptoms including low blood pressure, uncontrollable shaking, shivering, and body aches; testing later found excessive bacterial endotoxins in an unopened vial from the same lot. This example highlights why sterile-compounding quality can materially affect risk.

Who Should Use Extra Caution With NAD Injections?

Because safety data are limited, people who are pregnant or breastfeeding, have serious chronic medical conditions, take multiple medications, or are undergoing cancer treatment should discuss NAD injections with a qualified healthcare professional before use.

Evidence is not sufficient to define a comprehensive list of contraindications or drug interactions for injectable NAD+. A clinician should review current medications, allergies, relevant medical conditions, and the exact compounded formulation before treatment.

Managing and Minimizing Risk

Before Treatment

Before receiving injectable or IV NAD+, tell the clinician about your medications, supplements, allergies, previous reactions to injections or infusions, and medical conditions. Follow the preparation instructions supplied by the prescribing or administering clinician rather than relying on a universal NAD protocol.

If a compounded sterile NAD+ product is being considered, ask who prepared it and whether the pharmacy follows applicable sterile-compounding requirements.

During NAD+ Treatment

Report new symptoms promptly during treatment. For an IV infusion, the treating clinician may decide to slow or stop the infusion and evaluate the symptoms.

Do not assume chest pressure, severe nausea, marked dizziness, rapid heart rate, or shaking are a normal part of NAD therapy. Significant symptoms should be medically assessed.

After an Injection or Infusion

Follow the clinician’s instructions for post-treatment monitoring. Contact the treating provider if symptoms persist, worsen, or differ from what you were told to expect. Seek urgent care for severe or rapidly progressing symptoms.

NAD Benefits and Side Effects: Weighing Uncertain Benefits Against Known Risks

NAD injections are marketed for outcomes such as increased energy, improved cognition, recovery, and healthy aging, but clinical evidence demonstrating these benefits remains limited. That uncertainty should be considered alongside treatment cost, inconvenience, product-quality concerns, injection or infusion risks, and the limited long-term safety data.

A person who is considering NAD therapy should ask what specific outcome is being targeted, what evidence supports that use, what product will be administered, whether it is compounded, and what adverse effects or emergency plans the clinic has in place.

What Do Human Studies Tell Us?

2019 IV NAD+ Metabolome Pilot Study

A 2019 pilot study examined plasma and urine NAD+-related metabolites during and after a six-hour IV NAD+ infusion. It helped describe how infused NAD+ was handled in humans, but it was not designed to establish broad clinical effectiveness or a comprehensive adverse-event profile.

2026 Real-World IV NAD+ Tolerability Study

A 2026 retrospective pilot study reviewed commercially administered IV NAD+ and IV nicotinamide riboside. Participants receiving NAD+ reported gastrointestinal symptoms, increased heart rate, and chest pressure during infusions. The study provides useful preliminary tolerability information, but its small size, retrospective design, commercial setting, and short follow-up limit how broadly the results can be applied.

These studies do not establish a standardized NAD+ injection dose, prove anti-aging or energy benefits, or provide enough evidence to predict who will develop side effects.

What Is a NAD Shot?

A NAD shot generally refers to an intramuscular injection of a compounded NAD+-containing product. Because there is no FDA-approved NAD+ injection with standardized labeling for wellness indications, formulation, concentration, and administration instructions can vary.

Sterile technique and product quality are important for any injectable treatment. If repeated injections are prescribed, the clinician should provide instructions for site selection, administration, storage, and monitoring.

NAD in IV Protocols and Side-Effect Management

IV administration protocols vary by provider and compounded formulation. Infusion rate and response should be managed by the treating clinician, particularly if nausea, chest pressure, increased heart rate, cramping, dizziness, or other symptoms develop.

The presence of clinical staff does not eliminate risk, so facilities administering IV products should have appropriate procedures for recognizing and responding to adverse reactions.

Disclaimer

Disclaimer: This website connects patients with licensed healthcare providers who can evaluate medical conditions and prescribe medications when appropriate. Some medications available through this service may be compounded drugs, which are customized formulations prepared by a pharmacy. The FDA does not conduct premarket review for compounded drugs to evaluate their safety, effectiveness, or quality. (See here: https://www.fda.gov/consumers/consumer-updates/it-really-fda-approved). Individual results may vary, and these medications should only be used under the guidance of a qualified healthcare professional. The information in this article is for educational purposes only and should not be considered medical advice. Always consult your healthcare provider before starting any new treatment.